The Challenge
Nycomed retained PharmaBioSource as its transaction consultant to divest its 155,200-square-foot small molecule imaging research and development facility in Devon, Pennsylvania (suburban Philadelphia).
The Solution
PharmaBioSource marketed the facility to strategic acquirers.
Services provided by the PharmaBioSource team:
- Benchmark valuation
- Buyer target identification and engagement
- Creation of the Confidential Information Memorandum (CIM)
- Data room development
- Due diligence support
The Results
PharmaBioSource identified Merck & Co. as the acquirer. Merck acquired the facility with plans to convert the chemistry laboratories into microbiology labs to support testing of all of the company’s vaccine clinical trial samples. Merck also installed a cryogenic freezer farm and vaccine sample stability storage area in the facility, and planned to utilize the multi-function pilot plant for drug discovery purposes.
What We Did
Sell-Side Advisory
Facility Divestiture